AIM
ATYR

Acrospire Investment Management’s aTyr Pharma ATYR Stock Holding History

Acrospire Investment Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-906
Closed -$27K – 2538
2016
Q4 		$27K Buy
+906
New +$37.2K 0.01% 1677

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GHCM
Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return
MCIM
Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acrospire Investment Management's ATYR Position: Q1 2017 in Review

Acrospire Investment Management sold out of aTyr Pharma (ATYR) in Q1 2017, closing a stake of 906 shares — an estimated $27K sold.

Acrospire Investment Management first reported a position in ATYR in Q4 2016 and held it in 1 quarter. The position peaked at $27K in Q4 2016. 39 funds tracked by Wall St. Rank hold ATYR as of Q1 2017.

  • Acrospire Investment Management reported no remaining aTyr Pharma position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 906 aTyr Pharma shares in Q1 2017, an estimated $27K.
  • Acrospire Investment Management first reported a position in aTyr Pharma in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's aTyr Pharma position peaked at $27K in Q4 2016.
  • 39 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.